Rapid and sensitive immunoassay for the measurement of serum S100B using isoform-specific monoclonal antibody

Clinical Chemistry

Volumn 45, Issue 8 I, 1999, Pages 1307-1311

  Takahashi, Miyoko ^a   Chamczuk, Andrea ^a   Hong, Yuwen ^a   Jackowski, George ^a  

^a Skye Pharmatech Inc   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOCHEMICAL MARKER; CITRIC ACID; COMPLEMENTARY DNA; EDETIC ACID; MONOCLONAL ANTIBODY; PROTEIN S 100;

ADULT; AGED; ANIMAL EXPERIMENT; ARTICLE; BRAIN HEMORRHAGE; CEREBROSPINAL FLUID LEVEL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE AMPLIFICATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MOUSE; NONHUMAN; PROTEIN BLOOD LEVEL; STROKE; TRANSIENT ISCHEMIC ATTACK;

ANIMALIA;

EID: 0032878121     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/45.8.1307     Document Type: Article

References (27)

1. Moore BW. A soluble protein characteristic of the nervous system. Biochem Res Commun 1965;19:739-44.
2. Schafer BW, Wicki R, Engelkamp D, Mattel M-G, Heizmann CW. Isolation of a YAC clone covering a cluster of nine S100 genes on human chromosome 1q21: rationale for a new nomenclature of the S100 calcium-binding protein family. Genomics 1995;25:638-43.
3. Isobe T, Ishioka N, Okuyama T. Structural relation of two S 100 proteins in bovine brain: subunit composition of S-100a. Eur J Biochem 1981;115: 469-74.
4. Kimura S, Kato K, Semba R, Isobe T. Regional distribution of S-100ao (αα), S-100a (αβ) and S-100b (ββ) in the bovine central nervous tissue determined with a sensitive enzyme immunoassay system. Neurochem Int 1984;6:513-8.
5. Isobe T, Ishioka N, Matsuda T, Takahashi Y, Ganno S, Okuyama T. A rapid separation of S100 subunits by high performance liquid chromatography: the subunit compositions of S100 proteins. Biochem Int 1983;6:419-26.
6. Zimmer DB, Cornwall EH, Landar A, Song W. The S100 protein family: history, function and expression. Brain Res Bull 1995;37:417-29.
7. Michetti F, Massaro A, Murazio M. The nervous system-specific S-100 antigen in cerebrospinal fluid of multiple sclerosis patients. Neurosci Lett 1979;11:171-5.
8. Michetti F, Massaro A, Russo G, Rigon G. The S-100 antigen in cerebrospinal fluid as a possible index of cell injury in the nervous system. J Neurol Sci 1980;44:259-63.
9. Sindic CJM, Chalon MP, Cambiaso CL, Laterre EC, Masson PL. Assessment of damage to the central nervous system by determination of S-100 protein in the cerebrospinal fluid. J Neurol Neurosurg Psychiatry 1982;45:1130-5.
10. Mokuno K, Kato K, Matsuoka Y, Sobue Y. Neuron-specific enolase and S-100 protein levels in cerebrospinal fluid of patients with various neurological diseases. J Neurol Sci 1983;60:443-51.
11. Persson L, Hardemark H, Gustafsson J, Rundstrom G, Mendel-Hartvig I, Esscher T, Pahlman S. S 100 protein and neuron-specific enolase in cerebrospinal fluid and serum: markers of cell damage in human central nervous system. Stroke 1987;18:911-8.
12. Fagnart OC, Sindic CJM, Laterre C. Particle counting immunoassay of S100 protein in serum. Possible relevance in tumors and ischemic disorders of the central nervous system. Clin Chem 1988;34:1387-91.
13. Ingebrigtsen T, Romner B, Kongstad P, Langbakk B. Increased serum concentrations of protein S-100 after minor head injury: a biochemical serum marker with prognostic value? J Neurol Neurosurg Psychiatry 1995; 59:103-4.
14. Ingebrigtsen I, Romner B. Serial S-100 protein serum measurements related to early magnetic resonance imaging after minor head injury. J Neurosurg 1996;85:945-8.
15. Westaby S, Johnsson P, Parry AJ, Blomqvist S, Solem J-O, Alling C, et al. Serum S100 protein: a potential marker for cerebral events during cardio pulmonary bypass. Ann Thorac Surg 1996;61:88-92.
16. β levels during CABG and intracardiac operations. Ann Thorac Surg 1997;63:492-6.
17. β during cardiac operations. Ann Thorac Surg 1998;65:1645-50.
18. Kim JS, Yoon SS, Kim YH, Ryu JS. Serial measurement of interleukin-6, transforming growth factor-β, and S-100 protein in patients with acute stroke. Stroke 1996;27:1553-7.
19. Abraha HD, Butterworth RJ, Bath PMW, Wassif WS, Garthwaite J, Sherwood RA. Serum S-100 protein, relationship to clinical outcome in acute stroke. Ann Clin Biochem 1997;34:366-70.
20. Missler U, Wiesmann M, Friedrich C, Kaps M. S-100 protein and neuron-specific enolase concentrations in blood as indicators of infarct volume and prognosis in acute ischemic stroke. Stroke 1997;28:1956-60.
21. Buttner T, Weyers S, Postert T, Sprengelmeyer R, Kuhn W. S-100 protein: serum marker of focal brain damage after ischemic territorial MCA infarction. Stroke 1997;28:1961-5.
22. Fuller SA, Takahashi M, Hurrell JGR. Preparation of monoclonal antibodies. In: Ausubet FM, Brent R, Kingston RE, Moore DD, Seidman JG, Smith JA, Struhl K, eds. Current protocols in molecular biology. New York: Green Publishing Associates and Wiley Interscience, 1988:11.3.1-11.11.5.
23. Van Engelen BGM, Lamers KJB, Gabreels FJM, Wevers RA, van Geel WJA, Borm FG. Age-related changes of neuron-specific enolase, S-100 protein, and myelin basic protein concentrations in cerebrospinal fluid. Clin Chem 1992;38:813-6.
24. Nygaard O, Langbakk B, Romner B. Age- and sex-related changes of S-100 protein concentrations in cerebrospinal fluid and serum in patients with no previous history of neurological disorders. Clin Chem 1997;43:541-3.
25. Hardemark H-G, Ericsson N, Kotwica Z, Rundstrom G, Mendel-Hartvig I, Olsson Y, et al. S-100 protein and neuron-specific enolase in CSF after experimental traumatic or focal ischemic brain damage. J Neurosurg 1989; 71:127-31.
26. Aurell A, Rosengren LE, Karlsson B, Olsson J-E, Zbornikova V, Haglid KG. Determination of S-100 and glial fibrillary acidic protein concentrations in cerebrospinal fluid after brain infarction. Stroke 1991;22:1254-8.
27. Vuadens P, Bogousslavsky J. Diagnosis as a guide to stroke therapy. Stroke 1998;352(Suppl III):5-9, two of eight CT-negative patients.